Pharmaceutical Labeling Summit From FDAAA to SPL to REMS - Navigating the FDAs New Focus
Venue: National Press Club
|Event Date/Time: Jul 22, 2010|
Labeling has always been a factor, but today, approvals and revisions have taken on a whole new dimension with the FDAâ€™s new emphasis on careful deliberation and approval of new drugs (not to mention postmarket safety). Consider:
* The key drug labeling case of Wyeth v. Levine, in which the Supreme Court held that federal regulatory approval of a medication does not shield the manufacturer from liability under state law;
* Ongoing challenges with off-label promotion in the wake of hard-hitting prosecutions by U.S. attorneys resulting in multimillion-dollar legal settlements; and
* New SPL format rules and their effect on labeling and medical communications.
This coming July, there will be an exceptional opportunity to buttonhole key FDA players plus the top lawyers, industry experts and others able to clarify new labeling requirements.
Come to Washington July 22â€“23, 2010, when they will all be in one room, waiting to talk to you. Mark your calendar now for the Pharmaceutical Labeling Summit: From FDAAA to SPL to REMS â€” Navigating the FDAâ€™s New Focus